Literature DB >> 29845460

Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia.

Kazuyuki Sato1, Hirotaka Sakai2, Yusuke Saiki1, Akiko Uchida1, Yu Uemura1, Satoshi Yokoi1, Yuka Tsuruoka1, Yuji Nishio1, Manabu Matsunawa1, Yoshinori Suzuki1, Yasushi Isobe1, Masayuki Kato1, Naoto Tomita1, Yasuyuki Inoue1, Ikuo Miura1.   

Abstract

The introduction of all-trans retinoic acid (ATRA) has made acute promyelocytic leukemia (APL) a curable disease; however, early death prior to the completion of treatment remains a problem. In quantitative evaluation of response to ATRA treatment, lymphocytes must be excluded as they do not originally have t(15;17). We categorized peripheral blood leukocytes by nuclear morphology into polymorphonuclear cells (PMNs) comprising segmented granulocytes, and non-polymorphonuclear cells (NPMs) which includes lymphocytes, monocytes, band cells, and immature myeloid cells. We consecutively evaluated the ratio of t(15;17)-positive cells using fluorescence in situ hybridization in eight newly diagnosed patients with APL. We confirmed the differentiation of APL cells until cytogenetic complete remission; the association of a decrease of t(15;17)-positive NPMs and an increase of t(15;17)-positive PMNs was followed by a decrease of t(15;17)-positive PMNs. The kinetic pattern of t(15;17)-positive NPMs and PMNs was consistent in most patients, irrespective of leukocyte counts at diagnosis, additional chromosomal changes, and ATRA with or without chemotherapies. Kinetic analysis enables us to evaluate treatment response and the recovery of normal hematopoiesis in individuals.

Entities:  

Keywords:  Early death; Fluorescence in situ hybridization; PML–RARA; t(15;17)

Mesh:

Substances:

Year:  2018        PMID: 29845460     DOI: 10.1007/s12185-018-2472-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children.

Authors:  Anna Maria Testi; Andrea Biondi; Francesco Lo Coco; Maria Luisa Moleti; Fiorina Giona; Marco Vignetti; Giuseppe Menna; Franco Locatelli; Andrea Pession; Elena Barisone; Giulio De Rossi; Daniela Diverio; Concetta Micalizzi; Maurizio Aricò; Giuseppe Basso; Robert Foa; Franco Mandelli
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

2.  A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study.

Authors:  Norio Asou; Yuji Kishimoto; Hitoshi Kiyoi; Masaya Okada; Yasukazu Kawai; Motohiro Tsuzuki; Kentaro Horikawa; Mitsuhiro Matsuda; Katsuji Shinagawa; Tohru Kobayashi; Shigeki Ohtake; Miki Nishimura; Masatomo Takahashi; Fumiharu Yagasaki; Akihiro Takeshita; Yukihiko Kimura; Masako Iwanaga; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

Review 3.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

4.  Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

Authors:  S Lehmann; A Ravn; L Carlsson; P Antunovic; S Deneberg; L Möllgård; A Rangert Derolf; D Stockelberg; U Tidefelt; A Wahlin; L Wennström; M Höglund; G Juliusson
Journal:  Leukemia       Date:  2011-04-19       Impact factor: 11.528

5.  Early death in patients with acute promyelocytic leukemia. Proceedings from a live roundtable at the 2010 American Society of Hematology Annual Meeting, December 4–7, 2010, Orlando, Florida.

Authors:  Martin S Tallman; Francesco Lo-Coco; Hau C Kwaan; Miguel A Sanz; Steven D Gore
Journal:  Clin Adv Hematol Oncol       Date:  2011-02

Review 6.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

7.  Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.

Authors:  F Mandelli; R Latagliata; G Avvisati; P Fazi; F Rodeghiero; F Leoni; M Gobbi; F Nobile; E Gallo; R Fanin; S Amadori; M Vignetti; G Fioritoni; F Ferrara; A Peta; R Giustolisi; G Broccia; M C Petti; F Lo-Coco
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

8.  Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.

Authors:  Maaike Luesink; Jeroen L A Pennings; Willemijn M Wissink; Peter C M Linssen; Petra Muus; Rolph Pfundt; Theo J M de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

9.  All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Authors:  Martin S Tallman; Janet W Andersen; Charles A Schiffer; Frederick R Appelbaum; James H Feusner; William G Woods; Angela Ogden; Howard Weinstein; Lois Shepherd; Cheryl Willman; Clara D Bloomfield; Jacob M Rowe; Peter H Wiernik
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.

Authors:  P Fenaux; M C Le Deley; S Castaigne; E Archimbaud; C Chomienne; H Link; A Guerci; M Duarte; M T Daniel; D Bowen
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.